Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs bein...